Firm
Jacob Schroeder explains how he and his team secured victory for Promptu in a long-running patent infringement battle with Comcast
The Via members, represented by Licks Attorneys, target the Chinese company and three local outfits, adding to Brazil’s emergence as a key SEP litigation venue
The firm, which has revealed profits of £990,837, claims it is the disruptive force in the IP-legal industry
In the first of a two-parter, lawyers at Santarelli analyse the patentability of therapeutic inventions where publication of clinical trial protocols occurs before the application's filing date
Sponsored
Sponsored
-
Sponsored by Bird & BirdSeiko Hidaka of Bird & Bird and Kento Sumi, currently seconded to Bird & Bird, analyse a landmark decision in a standard-essential patent case and its implications for licensing practices and future litigation in Japan -
Sponsored by Wanhuida Intellectual PropertyJicheng Yang of Wanhuida Intellectual Property considers whether a notable Beijing Intellectual Property Court decision signals a change to assessing inventive step in polymorph patents in China
-
Sponsored by Hechanova GroupEditha R Hechanova, Brenda P Rivera, and Maricris V Faderugao of Hechanova Group examine new trademark and patent representative rules aimed at professionalising intellectual property services and aligning with global standards
-
Sponsored by RNA, Technology and IP AttorneysRanjan Narula and Parth Bajaj of RNA, Technology and IP Attorneys consider the potential impact of two US cases on Indian jurisprudence and what constitutes fair use of copyrighted material in training AI models
-
Sponsored by Tilleke & GibbinsThe measures represent a ‘strategic leap’ for Vietnam’s intellectual property landscape, say Thuy Thi Ngoc Huynh and Yen Thi Hai Pham of T&G Law Firm LLC (TGVN), the local associate firm of Tilleke & Gibbins
-
Sponsored by Hanol IP & LawMin Son of Hanol IP & Law analyses a ruling that clarifies the scope of patent infringement, territoriality limits, and research exemptions in a cross-border dispute over Pfizer’s pneumococcal vaccine
